Natural Product (NP) Details
| General Information of the NP (ID: NP6993) | |||||
|---|---|---|---|---|---|
| Name |
Arsenic trioxide
|
||||
| Synonyms |
Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+)
Click to Show/Hide
|
||||
| Disease | Leukaemia [ICD-11: 2A60-2B33] | Approved | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
As2O3
|
||||
| PubChem CID | |||||
| Canonical SMILES |
[O-2].[O-2].[O-2].[As+3].[As+3]
|
||||
| InChI |
1S/2As.3O/q2*+3;3*-2
|
||||
| InChIKey |
QTLQKAJBUDWPIB-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 1327-53-3
|
||||
| ChEBI ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| GM-CSF | Acute myelogenous leukemia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | JAK-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | PML | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | RARA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
| UF-1 | CVCL_0567 | Acute promyelocytic leukemia | Homo sapiens | |||
| In-vivo Model | Human GM-CSF-producing trans genic SCID (hGMTgSCID) mice were pretreated with 3 Gy of total body irradiation and then inoculated subcutaneously with UF-1 cells (1 * 107 cells) in their logarithmic growth phase. | |||||
| Experimental
Result(s) |
A combination of As2O3 and GM-CSF induces differentiation of APL cells both in vitro and in vivo. | |||||
| Gilteritinib | Acute myeloid leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ERN1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | FLT-3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MV4-11 | CVCL_0064 | Childhood acute monocytic leukemia | Homo sapiens | ||
| MOLM-13 | CVCL_2119 | Adult acute myeloid leukemia | Homo sapiens | |||
| THP-1 | CVCL_0006 | Childhood acute monocytic leukemia | Homo sapiens | |||
| HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | |||
| In-vivo Model | Xenograft tumors were generated by injecting subcutaneously 1*107 MV4-11 cells in 100 uL of PBS on left flank in nude mice. | |||||
| Experimental
Result(s) |
Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress. | |||||
| Cotylenin A | Acute myeloid leukemia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | IFI27 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells. | |||||
| LY294002 | Adrenal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| HT29 | CVCL_A8EZ | Colorectal adenocarcinoma | Mus musculus | |||
| Experimental
Result(s) |
Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002 synergistically inhibite colon carcinoma cell growth. | |||||
| Bacillus Calmette-Guerin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CD83 | Molecule Info | ||
| Up-regulation | Expression | FUN1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | GABPA | Molecule Info | |||
| Down-regulation | Expression | IER3 | Molecule Info | |||
| Up-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | NQO1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | 5637 | CVCL_0126 | Bladder carcinoma | Homo sapiens | ||
| In-vivo Model | 0.15 mL human bladder cancer cell suspension (with a concentration of 1 * 107 /ml) was injected through the catheter into the urinary bladder cavity. | |||||
| Experimental
Result(s) |
Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway. | |||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [7] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IVL | Molecule Info | |||
| Down-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NANOG | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | POU5F1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SAS | CVCL_1675 | Tongue squamous cell carcinoma | Homo sapiens | ||
| OECM-1 | CVCL_6782 | Gingival squamous cell carcinoma | Homo sapiens | |||
| In-vivo Model | To establish nude mouse transplantation tumor model, HN-CICs cells were subcutaneously injected into BALB/c nude mice (6-8 weeks). | |||||
| Experimental
Result(s) |
Combinatorial low dose arsenic trioxide and cisplatin exacerbates autophagy via AMPK/STAT3 signaling on targeting head and neck cancer Initiating cells. | |||||
| L-buthionine sulfoximine | Brain cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [8] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Activity | GSTK1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Caki-1 | CVCL_0234 | Clear cell renal cell carcinoma | Homo sapiens | ||
| Caki-2 | CVCL_0235 | Renal cell carcinoma | Homo sapiens | |||
| NC65 | Renal cell carcinoma | Homo sapiens | ||||
| Experimental
Result(s) |
BSO sensitizes RCC cells to As2O3-induced apoptosis through the down-regulation of the intracellular GSH redox system. | |||||
| Megestrol acetate | Cancer cachexia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [9] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | HepG2 cells were collected in 0.2 ml of PBS, and the cell suspensions were then injected subcutaneously into five-week-old BALB/C male nude mice (5*106 cells per mouse). | |||||
| Experimental
Result(s) |
MA/ATO combined treatment enhanced antitumor efficacy. | |||||
| PD184352 | Chronic lymphocytic leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [10] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Increase | Mitochondrial transmembrane potential | ||||
| Increase | Percentage of sub-G1 apoptotic cells | |||||
| In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
| Acute promyelocytic leukemia primary blasts derived from patients | Acute promyelocytic leukemia | Homo sapiens | ||||
| Experimental
Result(s) |
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. | |||||
| Dasatinib | Chronic myelogenous leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [11] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ATF-4 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | ATF2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BBC3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JUN | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SUP-B15 | CVCL_0103 | B acute lymphoblastic leukemia | Homo sapiens | ||
| TOM-1 | CVCL_1895 | B acute lymphoblastic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone. | |||||
| Recombinant mutant human TRAIL | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [12] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | ADAR | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | AIFM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CAPNS1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CBX3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | HNRNPK | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ILF3 | Molecule Info | |||
| Up-regulation | Expression | PCBP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | STAT1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | THRAP3 | Molecule Info | |||
| In-vitro Model | RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | ||
| U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | |||
| Experimental
Result(s) |
ATO and rmhTRAIL had synergistic or additive effects on proliferation inhibition and apoptosis induction in MM cells, and the mechanism underlying the two-drug combination might involve regulation of the expression of several proteins affected by ATO and rmhTRAIL. | |||||
| 1,25-dihydroxyvitamin D3 | Congenital alopecia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [13] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis. | |||||
| Androgen | Diminished ovarian reserve | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [14] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | ATG5 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | CYB5R2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
| PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells. | |||||
| Valproic acid | Epilepsy/seizure | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [15] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
| NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combination of arsenic trioxide and valproic acid efficiently inhibits growth of lung cancer cells via G2/M-phase arrest and apoptotic cell death. | |||||
| Itraconazole | Fungal infection | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [16] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H929 | CVCL_1600 | Plasma cell myeloma | Homo sapiens | ||
| Experimental
Result(s) |
ATO combined with ITRA can more strongly suppress the growth of multiple myeloma NCI-H929 cells, as compared with a single administration. The synergistic effect of ATO and ITRA significantly down-regulates expression of Gli1 in HH signaling pathway, moreover the inhibition of target gene overexpression may be one of two drug mechanisms. | |||||
| PD98059 | Gastrointestinal stromal tumor | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [10] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Increase | Mitochondrial transmembrane potential | ||||
| Increase | Percentage of sub-G1 apoptotic cells | |||||
| In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
| Acute promyelocytic leukemia primary blasts derived from patients | Acute promyelocytic leukemia | Homo sapiens | ||||
| Experimental
Result(s) |
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. | |||||
| 1,3-bis(2-chloroethyl)-1-nitrosourea | Hepatocellular carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [17] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HONE-1 | CVCL_8706 | Nasopharyngeal carcinoma | Homo sapiens | ||
| DBTRG-05MG | CVCL_1169 | Anaplastic astrocytoma | Homo sapiens | |||
| HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
| NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
| A2058 | CVCL_1059 | Amelanotic melanoma | Homo sapiens | |||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| TSGH | Gastric carcinoma | Homo sapiens | ||||
| Experimental
Result(s) |
Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors. | |||||
| Canstatin | Hepatocellular carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [18] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PCNA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| In-vivo Model | To establish nude mouse transplantation tumor model, 0.2 ml of HepG2 cells (1 * 107/ml) were injected subcutaneously in the right axilla of mice. | |||||
| Experimental
Result(s) |
Combined canstatin and ATO significantly inhibited cell proliferation, migration and adhesion abilities, and promoted cell apoptosis, and inhibited tumor growth, thus suppressed the progression of HCC. | |||||
| Docosahexaenoic acid | Hyper-lipoproteinaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [19] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. | |||||
| Deferoxamine | Low bone mass disorder | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [20] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| In-vivo Model | The tumor xenograft model was established by subcutaneous inoculation of cultured HL-60 cells (1.0 * 107/ml) in 0.1 ml Hank's balanced salt solution (HBSS) into the right axilla back region of female BALB/c-nu/nu nude mice (3-5weeks of age). | |||||
| Experimental
Result(s) |
Combination of DFO and ATO has synergistic effects on tumor growth inhibition and apoptosis-inducing in vivo with no significant side effects. | |||||
| BIBR1532 | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [21] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TERT | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFC | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G1 phase | ||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-231 | Breast cancer | Homo sapiens | ||||
| Experimental
Result(s) |
Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-KappaB signaling pathway. | |||||
| Gefitinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [22] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | ITGAM | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | NDUFA2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line. | |||||
| MG132 | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [23] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BNIP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | ||
| Raji | CVCL_0511 | EBV-related Burkitt lymphoma | Homo sapiens | |||
| Experimental
Result(s) |
Synergism between ATO and MG132 was attained in Raji cells by disruption of the perinuclear mitochondrial cluster, blockage of selective autophagy of mitochondria (mitophagy) by VCR, increased mitochondrial mass, and upregulation of BNIP3 by VPA. | |||||
| TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [24] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | ML1 | CVCL_0436 | Adult acute myeloid leukemia | Homo sapiens | ||
| K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | |||
| Raji | CVCL_0511 | EBV-related Burkitt lymphoma | Homo sapiens | |||
| PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
| HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | |||
| COLO 205 | CVCL_0218 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. | |||||
| Buthionine sulfoximine | Malaria | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [25] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| Namalwa | CVCL_0067 | EBV-related Burkitt lymphoma | Homo sapiens | |||
| Jurkat | CVCL_0065 | T acute lymphoblastic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Buthionine Sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. | |||||
| Chloroquine | Malaria | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [26] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
CQ exhibits a cytotoxic effect on NB4 cells and has a synergistic effect when combined with ATO, which thereby improves the curative effect of ATO on APL. | |||||
| Bortezomib | Mantle cell lymphoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [27] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Induction | Degradation | PRAM1 | Molecule Info | |||
| Induction | Degradation | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Increase | ROS generation | ||||
| Increase | Unfold protein response | |||||
| In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
| HS-5 | CVCL_3720 | Healthy | Homo sapiens | |||
| In-vivo Model | APL cells (5 * 104 cells/mouse) were injected intravenously via the tail vein into genetically compatible FVB/N recipients, without conditioning with either radiation or chemotherapy. | |||||
| Experimental
Result(s) |
A synergistic effect on combining ATO and bortezomib in vitro was noted in both ATO-sensitive and ATO-resistant APL cell lines. The mechanism of this synergy involved downregulation of the nuclear factor-KappaB pathway, increase in unfolded protein response (UPR) and an increase in reactive oxygen species generation in the malignant cell. | |||||
| Imatinib | Mantle cell lymphoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [28] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABL | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | ||
| Experimental
Result(s) |
As2O3 in combination with imatinib showed favorable cytotoxicity and proapoptotic activity in chronic myelogenous leckemia. | |||||
| Polyinosinic acid-polycytidylic acid | Middle East Respiratory Syndrome | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [29] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TLR3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SMMC-7721 | CVCL_0534 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells. | |||||
| Lenalidomide | Multiple myeloma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [30] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IL10 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | NFKBIA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | BC-3 | CVCL_1080 | Primary effusion lymphoma | Homo sapiens | ||
| BCBL-1 | CVCL_0165 | Primary effusion lymphoma | Homo sapiens | |||
| In-vivo Model | Six to eight week old immuno-compromised male or female NOD/SCID mice were inoculated with 2 million BC-3 or BCBL-1 cells. | |||||
| Experimental
Result(s) |
Lenalidomide in combination with arsenic trioxide is an effective therapy for primary effusion lymphoma. | |||||
| Lithium chloride | Multiple myeloma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [31] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | GSK-3B | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | RD | CVCL_1649 | Embryonal rhabdomyosarcoma | Homo sapiens | ||
| Rh30 | CVCL_0041 | Alveolar rhabdomyosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines. | |||||
| Thalidomide | Multiple myeloma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [32] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MEK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PTEN | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ULK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | VEGFC | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | KG-1 | CVCL_0374 | Adult acute myeloid leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Arsenic trioxide and thalidomide combination induces autophagy along with apoptosis in acute myeloid cell lines. | |||||
| Vorinostat | Mycosis fungoides | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [33] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
| In-vivo Model | Male Balb/c nude mice at 4-6 weeks of age were injected sc in the hind limb with 1 * 107 H1299 cells in 100 ul of phosphate-buffered saline. | |||||
| Experimental
Result(s) |
Combined treatment with ATO and SAHA resulted in enhanced suppression of non-small-cell lung carcinoma in vitro in H1299 cells and in vivo in a xenograft mouse model. | |||||
| Azacitidine | Myelodysplastic syndrome | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [34] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | XAF1 | Molecule Info | ||
| In-vitro Model | 8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | ||
| XG-7 | CVCL_A772 | Plasma cell myeloma | Homo sapiens | |||
| Experimental
Result(s) |
Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. | |||||
| Nilotinib | Myeloproliferative neoplasm | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [35] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BTG1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | TAL1 | Molecule Info | |||
| In-vitro Model | Cells derived from the bone marrow of CML-BC patients | Chronic Myelogenous Leukemia | Homo sapiens | |||
| Experimental
Result(s) |
ATO and nilotinib treatment alone or in combination greatly suppressed cell proliferation but promoted the differentiation of CML-BC cells towards multiple-lineages. | |||||
| PD173074 | Nasopharyngeal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [36] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | c-RAF | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | FGFR1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SRC | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-MES-1 | CVCL_0630 | Lung squamous cell carcinoma | Homo sapiens | ||
| SW900 | CVCL_1731 | Lung squamous cell carcinoma | Homo sapiens | |||
| NCI-H2170 | CVCL_1535 | Lung squamous cell carcinoma | Homo sapiens | |||
| In-vivo Model | The SK-MES-1 xenograft model was developed by subcutaneous injection of 1*107 cells with Matrigel into the upper back of 40 nude mice (female, 4-6-week-old, 10-14 g, BALB/cAnN-nu). | |||||
| Experimental
Result(s) |
Combined ATO/PD173074 reduced cell viability along with increased sub-G1 population, phosphatidylserine externalization and mitochondrial membrane depolarization more significantly than single treatments. | |||||
| ABT-737 | Ovarian cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [37] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | ||
| MGC-803 | CVCL_5334 | Gastric mucinous adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo. | |||||
| Lonidamine | Prostate hyperplasia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [38] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | |||
| RPMI-8866 | CVCL_1668 | Chronic myelogenous leukemia | Homo sapiens | |||
| Experimental
Result(s) |
lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO) to induce apoptosis in HL-60 and other human leukemia cell lines, with low toxicity in non-tumor peripheral blood lymphocytes. | |||||
| 2-methoxyestradiol | Pulmonary hypertension | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [39] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SV-HUC-1 | CVCL_3798 | Healthy | Homo sapiens | ||
| NTUB1 | CVCL_RW29 | Bladder carcinoma | Homo sapiens | |||
| T24 | CVCL_0554 | Bladder carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
2-Methoxyestradiol Induces Mitotic Arrest, Apoptosis, and Synergistic Cytotoxicity with Arsenic Trioxide in Human Urothelial Carcinoma Cells. | |||||
| Everolimus | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [40] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | ||
| LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
| In-vivo Model | Six-week-old SCID (severe combined immuno deficiency) mice were inoculated with 100 ul (50% Matrigel/PBS) LNCaP cells suspension (6 * 106) to either dorsal flank with 25-gauge syringe. | |||||
| Experimental
Result(s) |
Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells. | |||||
| Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [41] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BRAF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | c-RAF | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MEK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MEK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PTEN | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ULK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | KG-1 | CVCL_0374 | Adult acute myeloid leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
The combination effect of ATO and sorafenib in AML cell lines is apoptotic and autophagy. | |||||
| 2-deoxy-D-glucose | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [42] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | MEK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | PRKAA2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | STK11 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | |||
| THP-1 | CVCL_0006 | Childhood acute monocytic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: Involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/ AMPK signaling pathways. | |||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [43] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
As2O3 in combination with 5-FU treatment caused up-regulation of DR5, caspase 3, caspase 8, and caspase 9, and down-regulation of BCL-2, but had no effect of DR4. | |||||
| Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [44] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CORO1A | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | SKP2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PaTu 8988s | CVCL_1846 | Pancreatic adenocarcinoma | Homo sapiens | ||
| PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Arsenic trioxide inhibits Skp2 expression to increase chemosensitivity to gemcitabine in pancreatic cancer cells. | |||||
| PX-478 | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [45] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | FOXO1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | HIF-1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| BxPC-3 | CVCL_0186 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma. | |||||
| Etoposide | Testicular carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [46] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-673 | CVCL_0080 | Ewing sarcoma | Homo sapiens | ||
| RD-ES | CVCL_2169 | Ewing sarcoma | Homo sapiens | |||
| SK-N-MC | CVCL_0530 | Ewing sarcoma | Homo sapiens | |||
| mesenchymal stem cell | Healthy | Homo sapiens | ||||
| Experimental
Result(s) |
Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas. | |||||
| Cell differential agent-II | Acute lymphoblastic leukemia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [47] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Induction | Cell cycle arrest | ||||
| In-vitro Model | BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | ||
| Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
CDA-II can strongly potentiate As(2)O(3)-induced apoptosis in hepatoma cells, and two drugs can produce a significant synergic effect. | |||||
| 10058F4 | Acute myeloid leukemia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [48] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Cells derived from glioblastoma multiforme patients | Glioblastoma multiforme | Homo sapiens | |||
| In-vivo Model | For in vivo experiments, CSCs (5 * 104 cells) were implanted intracranially into 10 week-old female C.B17-lcr SCID mice. | |||||
| Experimental
Result(s) |
Arsenic trioxide drastically enhanced the anti-proliferative effect of 10058F4 but not apoptotic effects. | |||||
| Dithiothreitol | Cholestasis | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [49] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | The co-treatment of the carcinogen 4-NQO (200 ug/ml) plus arecoline (500 ug/ml) in the drinking water for eight weeks to C57BL-6 mice specifically induced tongue cancer within a further 20 weeks. | |||||
| Experimental
Result(s) |
Arsenic trioxide plus dithiothreitol showed synergistic cytotoxic effects on mice oral cancer cells. | |||||
| Decitabine | Myelodysplastic syndrome | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [50] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | MV4-11 | CVCL_0064 | Childhood acute monocytic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Effect of decitabine in combination with arsenic trioxide on prolife-ration and apoptosis of human acute myeloid leukemia MV4-11 cells. | |||||
| Ganciclovir | Virus infection | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [51] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | CNE1 < BX1 > cells (7.5*106 cells/mouse) were trypsinized and mixed with growth factor reduced matrigel and injected subcutaneously on the right flank of each mouse. | |||||
| Experimental
Result(s) |
Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma. | |||||
| β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Trolox | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [52] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | HSPA4 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | P388 | CVCL_7222 | Mouse lymphoma | Mus musculus | ||
| In-vivo Model | To establish xenograft model, P388 cells were injected i.p. in DBA/2 mice. | |||||
| Experimental
Result(s) |
Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. | |||||
| γ. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
| Rapamycin | Multiple myeloma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [53] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MDA-MB-468 | CVCL_0419 | Breast adenocarcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | |||
| T-47D | CVCL_0553 | Invasive breast carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | I-kappa-B-kinase beta (IKKB) | Molecule Info | [54] | |
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | Ras signaling pathway | |||
| 3 | Chemokine signaling pathway | |||
| 4 | NF-kappa B signaling pathway | |||
| 5 | FoxO signaling pathway | |||
| 6 | mTOR signaling pathway | |||
| 7 | PI3K-Akt signaling pathway | |||
| 8 | Apoptosis | |||
| 9 | Osteoclast differentiation | |||
| 10 | Toll-like receptor signaling pathway | |||
| 11 | NOD-like receptor signaling pathway | |||
| 12 | RIG-I-like receptor signaling pathway | |||
| 13 | Cytosolic DNA-sensing pathway | |||
| 14 | T cell receptor signaling pathway | |||
| 15 | B cell receptor signaling pathway | |||
| 16 | TNF signaling pathway | |||
| 17 | Neurotrophin signaling pathway | |||
| 18 | Insulin signaling pathway | |||
| 19 | Adipocytokine signaling pathway | |||
| 20 | Type II diabetes mellitus | |||
| 21 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 22 | Epithelial cell signaling in Helicobacter pylori infection | |||
| 23 | Shigellosis | |||
| 24 | Chagas disease (American trypanosomiasis) | |||
| 25 | Toxoplasmosis | |||
| 26 | Hepatitis C | |||
| 27 | Hepatitis B | |||
| 28 | Influenza A | |||
| 29 | HTLV-I infection | |||
| 30 | Herpes simplex infection | |||
| 31 | Epstein-Barr virus infection | |||
| 32 | Pathways in cancer | |||
| 33 | MicroRNAs in cancer | |||
| 34 | Pancreatic cancer | |||
| 35 | Prostate cancer | |||
| 36 | Chronic myeloid leukemia | |||
| 37 | Acute myeloid leukemia | |||
| 38 | Small cell lung cancer | |||
| Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
| 2 | B cell activation | |||
| 3 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 4 | Interleukin signaling pathway | |||
| 5 | PDGF signaling pathway | |||
| 6 | T cell activation | |||
| 7 | Toll receptor signaling pathway | |||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
| 2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
| 2 | BCR signaling pathway | |||
| 3 | GMCSF-mediated signaling events | |||
| 4 | Atypical NF-kappaB pathway | |||
| 5 | TCR signaling in naï | |||
| 6 | ||||
| 7 | Canonical NF-kappaB pathway | |||
| 8 | TRAIL signaling pathway | |||
| 9 | TCR signaling in naï | |||
| 10 | ||||
| 11 | FAS (CD95) signaling pathway | |||
| 12 | IL1-mediated signaling events | |||
| 13 | mTOR signaling pathway | |||
| 14 | TNF receptor signaling pathway | |||
| 15 | FoxO family signaling | |||
| 16 | p75(NTR)-mediated signaling | |||
| 17 | Validated transcriptional targets of TAp63 isoforms | |||
| 18 | Endogenous TLR signaling | |||
| Reactome | Activation of NF-kappaB in B cells | Click to Show/Hide | ||
| 2 | NOD1/2 Signaling Pathway | |||
| 3 | RIP-mediated NFkB activation via ZBP1 | |||
| 4 | p75NTR recruits signalling complexes | |||
| 5 | NF-kB is activated and signals survival | |||
| 6 | FCERI mediated NF-kB activation | |||
| 7 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
| 8 | Interleukin-1 signaling | |||
| 9 | Regulation of TNFR1 signaling | |||
| 10 | TNFR1-induced NFkappaB signaling pathway | |||
| 11 | IKBKB deficiency causes SCID | |||
| 12 | IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | |||
| 13 | IkBA variant leads to EDA-ID | |||
| 14 | CLEC7A (Dectin-1) signaling | |||
| 15 | MAP3K8 (TPL2)-dependent MAPK1/3 activation | |||
| 16 | TRAF6 mediated NF-kB activation | |||
| 17 | NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | |||
| 18 | IRAK1 recruits IKK complex | |||
| 19 | IKK complex recruitment mediated by RIP1 | |||
| 20 | IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | |||
| WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
| 2 | Estrogen signaling pathway | |||
| 3 | TCR Signaling Pathway | |||
| 4 | Insulin Signaling | |||
| 5 | IL-4 Signaling Pathway | |||
| 6 | MAPK Signaling Pathway | |||
| 7 | NLR Proteins | |||
| 8 | Hair Follicle Development: Induction (Part 1 of 3) | |||
| 9 | MyD88 cascade initiated on plasma membrane | |||
| 10 | Cardiac Hypertrophic Response | |||
| 11 | Cytosolic sensors of pathogen-associated DNA | |||
| 12 | MyD88 dependent cascade initiated on endosome | |||
| 13 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||
| 14 | MyD88:Mal cascade initiated on plasma membrane | |||
| 15 | Fc epsilon receptor (FCERI) signaling | |||
| 16 | MyD88-independent cascade | |||
| 17 | Signaling by the B Cell Receptor (BCR) | |||
| 18 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
| 19 | Structural Pathway of Interleukin 1 (IL-1) | |||
| 20 | EBV LMP1 signaling | |||
| 21 | Polycystic Kidney Disease Pathway | |||
| 22 | Apoptosis | |||
| 23 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
| 24 | BDNF signaling pathway | |||
| 25 | Interleukin-11 Signaling Pathway | |||
| 26 | AGE/RAGE pathway | |||
| 27 | TNF alpha Signaling Pathway | |||
| 28 | B Cell Receptor Signaling Pathway | |||
| 29 | IL17 signaling pathway | |||
| 30 | TWEAK Signaling Pathway | |||
| 31 | Leptin signaling pathway | |||
| 32 | RANKL/RANK Signaling Pathway | |||
| 33 | Signalling by NGF | |||
| 34 | IL-1 signaling pathway | |||
| 35 | TCR signaling | |||
| 36 | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
| 37 | Interleukin-1 signaling | |||
| 38 | Apoptosis Modulation and Signaling | |||
| 39 | Type II diabetes mellitus | |||
| 40 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 41 | Regulation of toll-like receptor signaling pathway | |||
| 42 | Osteopontin Signaling | |||
| 43 | NOD pathway | |||
